AMOON - Key Persons
Job Titles:
- Principal
- Principal at AMoon Growth
Adam is a Principal at aMoon Growth, where he leverages his expertise in finance and strategic analysis to identify and evaluate late-stage investment opportunities.
Prior to joining aMoon, Adam was an investment banker at Credit Suisse focusing on M&A in the African market across a multitude of sectors. Most notable was his advisory role for Anglo American Platinum on their disposal of selected mining assets in South Africa.
Adam also worked in Corporate Development at ADAMA Agricultural Solutions, one of the largest global manufacturers of generic plant protection products. During this time, he took a leading role in valuation, due diligence, and business negotiations across M&A and strategic commercial arrangements.
From an early age, Adam has nurtured a strong curiosity for the life sciences supported by the presence of doctors and engineers within his family.
He holds a Business Science Degree in Finance and Economics from the University of Cape Town.
Job Titles:
- Associate
- Associate in AMoon Growth
Addie is an Associate in aMoon Growth and Edge, where she helps oversee the fund's private and public healthcare investments.
A scientist and strategist, Addie has deep expertise across oncology, diagnostics, and digital health. She began her career in cancer research, earning her Ph.D. in Pharmacology from the Hebrew University of Jerusalem, where her work on tumor resistance mechanisms was published and presented internationally.
After a postdoctoral fellowship at Weill Cornell, she served as the Senior Advisor to the Consul General of Israel in New York, where she was deeply involved in forming diplomatic and business collaborations, and conducted due diligence on various healthcare projects throughout the Covid-19 pandemic for Israeli-American initiatives. She then transitioned into health strategy, consulting for top pharma and biotech clients at ClearView Healthcare Partners in New York.
Addie has received over a dozen awards for academic excellence and leadership, including the prestigious Israel Academy of Sciences and Humanities - The de Rothschild Fund for the Advancement of Science grant, Fraunhofer Institutes - Women International Campus leadership program, and the Na'amat Award for Promising Women Scientists.
Addie enjoys running and ran the New York City half marathon with her husband in 2023. She currently lives in Israel with her husband and twin baby boys.
Job Titles:
- Receptionist
- Receptionist at AMoon 's Israel
Adi is a receptionist at aMoon's Israel office. She is currently pursuing a double major in Sociology & Anthropology and Labor Studies at Tel Aviv University. Before joining aMoon, she served as an Office Manager for a global manufacturer specializing in healthcare, where she honed her organizational and interpersonal skills.
Adi completed her mandatory military service in 2021 as a Field Observer Commander, leading teams and ensuring operational efficiency in high-pressure environments. This background fuels her passion for understanding people, systems, and the intersection of culture and work.
When she's not studying or working, Adi enjoys exploring the stories behind data and the dynamics that drive human behavior.
David is a Controller at aMoon, where he is part of the finance team.
David has always been intrigued by the Israeli VC ecosystem and is inspired and motivated by aMoon's mission to be at the epicenter of innovation in Israel's HealthTech industry.
Previously, David worked as a Senior Accountant at Reznik Paz Nevo Accountants, where he audited financial reports for companies across a variety of industries as well as R&D financial reports for the Israeli Innovation Authority.
David holds a BA in Accounting and Business Administration from IDC Herzliya, Arison School of Business Administration.
David is an Analyst at aMoon Velocity, where he leverages his medical expertise and strategic insight to identify and evaluate early-stage investment opportunities. David is also a member of the internal value-creation team, Alpha, supporting aMoon's portfolio companies' success.
A medical doctor by training, David earned his MD from the University of the Witwatersrand in Johannesburg. He went on to work in public hospitals in and around Cape Town, spending two years based at the renowned Groote Schuur Hospital. This hands-on clinical experience gives David a unique perspective on the healthcare ecosystem, which he brings to his work in life sciences investment.
David's passion for healthcare and innovation is deeply rooted in his upbringing in Johannesburg, where he was inspired by the challenges and opportunities in advancing medical care.
Dr Filozof is Vice President and Therapeutic Area Head in Obesity, MASH and Liver indications in Fortrea. Her expertise is broad and ranges from clinical trials and drug development to Global medical affairs, market launches, all on a global scale and across multiple therapy areas, including Obesity, Diabetes (T2DM), dyslipidemias, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and multiple hepatology indications and rare diseases.
Dr Filozof joined Fortrea (previously Covance/Labcorp) 10 years ago and has been consulting with several sponsor with strategic study design, helping them to generate high quality data in the most efficient way. She also brings experience in innovative study design and has chaired the multi-functional innovative study designs working group at Fortrea for the last 3 years.
Dr. Daniel Sass is a South African-trained doctor with a diverse background across clinical practice and health technology. He earned his medical degree from the University of the Witwatersrand and furthered his training in Emergency Medicine through the Colleges of Medicine of South Africa. He spent much of his clinical career on the frontlines of emergency departments in Cape Town, gaining firsthand insight into healthcare delivery under pressure.
In 2021, Daniel relocated to Israel to pursue an MBA in Technology, Entrepreneurship, and Innovation at Tel Aviv University. Prior to joining aMoon, he served as Director of Sales and Business Development at Pheno.AI, a company building the world's deepest phenotype dataset of human health and disease to unlock the future of AI-driven precision medicine. There, he worked closely with the CEO and leadership team to scale the Human Phenotype Project globally.
Daniel is passionate about working at the intersection of health, technology, and business to improve human health at scale. At aMoon, he leverages his clinical and business background to evaluate late-stage investment opportunities for the firm's Growth Fund. With a unique blend of medical and commercial expertise, he is driven by a deep commitment to improve human health at scale.
Health is also deeply personal for Daniel. A dedicated Ironman athlete, he has competed in numerous Ironmans, marathons, and ultramarathons across Africa, Europe, and the Middle East-reflecting the same endurance and discipline he brings to his professional pursuits.
The Honorable Dr. David J. Shulkin was the ninth Secretary of the US Department of Veterans Affairs in the Trump Administration and VA's Under Secretary of Health in the Obama Administration. As such, Secretary Shulkin was the only member of the Cabinet to have served both Presidents and to have been confirmed by the US Senate by a vote of 100-0.
As Secretary, Dr. Shulkin represented the 21 million American veterans and was responsible for the nation's largest integrated healthcare system with over 1,200 sites of care, serving over 9 million Veterans. VA is also the nation's largest provider of graduate medical education and major contributor of medical research and provides veterans with disability payments, education through the GI bill, home loans, and runs a national cemetery system.
Secretary Shulkin is a widely respected healthcare executive having served as chief executive of leading hospitals and health systems including Beth Israel in New York City, Morristown Medical Center in Northern NJ, and currently advises leading health systems. Secretary Shulkin has held numerous physician leadership roles including the Chief Medical Officer of the University of Pennsylvania Health System, the Hospital of the University of Pennsylvania, Temple University Hospital, and the Medical College of Pennsylvania Hospital. Secretary Shulkin has held academic positions including the Chairman of Medicine and Vice Dean at Drexel University School of Medicine. As an entrepreneur, he founded and served as the Chairman and CEO of DoctorQuality, one of the first consumer orientated sources of information for quality and safety in healthcare. Secretary Shulkin has served on boards of managed care companies, technology companies, and healthcare organizations. He now works with healthcare organizations that are leading the transformation of medicine around the world.
Secretary Shulkin is a board-certified internist. He received his medical degree from the Medical College of Pennsylvania, his internship at Yale University School of Medicine, and a residency and Fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania.
Over his career, Secretary Shulkin has been named "One Hundred Most Influential People in American Healthcare" by Modern Healthcare. He continues to advocate on behalf of the country's veterans by serving on the board of numerous nonprofits that serve veterans, is the host of the popular Policy Vets Podcast, and is the author of the recent book, "It Shouldn't Be This Hard to Serve Your Country: Our Broken Government and the Plight of Veterans."
Job Titles:
- Associate
- Associate at AMoon Growth
Dr. Rey Mozer is an Associate at aMoon Growth, where she focuses on sourcing and evaluating late-stage investment opportunities in HealthTech and MedTech. With over a decade of clinical experience and a background in healthcare strategy, she brings a unique perspective to identifying opportunities at the intersection of patient care, technology, and operational innovation. She is passionate about driving systemic change in healthcare through scalable, tech-enabled solutions, and works closely with management teams to support value creation and accelerate growth across the portfolio.
Prior to joining aMoon, Rey was a consultant at McKinsey & Company, where she advised leading MedTech, digital health, and healthcare organizations on growth strategy, innovation, and AI-driven transformation. Earlier in her career, she was a practicing pediatric radiologist at Boston Children's Hospital / Harvard Medical School and Tufts Medical Center.
Rey holds an MD from Yale School of Medicine, an MBA from the Wharton School, and a BA in Biology from Cornell University (cum laude). She completed her residency and fellowship training at Brigham and Women's Hospital and Boston Children's Hospital.
Job Titles:
- Strategic Advisor of Minderoo Foundation 's Collaborate Against Cancer Initiative
Dr. Steve Burnell is a Strategic Advisor of Minderoo Foundation's Collaborate Against Cancer Initiative, leads Minderoo's COVID-19 Response and is establishing a research program in marine genomics. Steve has a dual passion for working at the intersections of technology with healthcare and our environment, being particularly focused on how to improve the way data is used to improve cancer care and marine conservation. He joined Minderoo Foundation from the Roche Group, the world's largest biotech, where he has run global businesses in diagnostics and more recently established a new informatics and real-world data business in oncology.
Steve's 30+ years experience in research and business spans academia, strategy consulting, healthcare and personalized medicine. He holds a B.Sc. with honors in Biology and a Ph.D. in Population Biology from the University of Sydney, Australia. Steve and his family relocated to Perth, Australia from the San Francisco Bay area in January 2020.
Dr. Tomer Berkovitz is a Managing Partner at aMoon. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.
Since joining aMoon in February 2018, Tomer has led investments and served on the board of directors of several HealthTech companies, including Seer (NASDAQ:SEER), SOPHiA GENETICS (NASDAQ: SOPH), Sera Prognostics (NASDAQ: SERA), PrognomIQ, Zebra Medical Vision (acquired by Nanox, NASDAQ: NNOX), Omada Health, and others.
Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he led HealthCare in its Corporate Finance Advisory team. In this position, he played a key role in numerous capital market transactions and mergers and acquisitions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra, a NASDAQ-listed biopharmaceutical company, where he led public equity offerings and its merger with Arcturus Therapeutics.
Tomer earned his Ph.D. in Finance (with Distinction) from Columbia Business School and published his research work in leading academic and practitioner journals. He also holds a B.A. in Economics and Management (Magna Cum Laude) and M.Sc. in Finance and Accounting (Magna Cum Laude), both from Tel Aviv University.
Job Titles:
- Advisor
- Co - Founder
- Managing Partner
Dr. Yair Schindel is the Co-Founder & Managing Partner of aMoon.
As a healthcare entrepreneur, investor, and physician with vast experience in the field, Yair co-founded aMoon in 2017.
Born into a family of physicians, Yair's parents and grandparents are doctors. His grandparents were Schindler's List Holocaust survivors who escaped Auschwitz-Birkenau death camps and rebuilt their lives in the state of Israel. Growing up, Yair internalized their strength and held a deep appreciation for the sanctity of life. Driven toward a life in medicine and motivated by a desire to save lives and give back to the world, Yair began his career as a physician, but soon pivoted to a life in innovation. Establishing aMoon is the realization of his life's work in the fields of healthcare, technology, and digital transformation.
Before launching aMoon, Yair served as the founding CEO of Digital Israel, the State's National Digital Bureau established within the Israeli Prime Minister's Office to accelerate digital transformation and stimulate economic growth on a national level.
Prior to Digital Israel, Yair was the CEO of Startup Nation Central, a nonprofit organization that connects major international businesses, governments, and NGOs to Israeli innovation.
In 2010, Yair co-founded MAOZ, an NGO that trains and connects Israel's most promising future leaders, creating an active network of over 500 alumni promoting social change initiatives to strengthen Israel's socio-economic resilience. Between 2011 to 2013, Yair served as the organization's founding CEO, and until 2016, as a board member.
In the private sector, Yair served as an executive, investor, board member, or advisory board member in several healthcare startups, including OmniGuide, MDClone, Medisafe, Zebra, Adicet (NASDAQ:ACET), CartiHeal, Igentify, and DayTwo.
When Yair founded aMoon, he also established a parallel nonprofit organization - The 8400 Health Network. With Yair as the Co-founder and Chairman, 8400 is building a coalition of public, private, and nonprofit sector leaders to build a national HealthTech growth engine.
Yair earned his BSc and MD degrees at Ben-Gurion University's Goldman Medical School and his MBA at the Harvard Business School. He currently serves on the Health Care Advisory Board at HBS. Prior to business school, Yair served for five years as a physician with IDF Special Forces. In his last position, Yair was the Chief Medical Officer for the Israeli Navy Seals, also known as "Shayetet 13."
Job Titles:
- Advisor
- Director of Operations
Elinor is the Director of Operations at aMoon, where she manages all aspects of aMoon's office and operational processes. Elinor was initially drawn to aMoon because of the organization's vision - healthcare is a topic that touches everyone, and she was attracted to the idea of being part of a group that is aspiring to find solutions to healthcare's greatest cost drivers.
Elinor brings to aMoon more than 20 years of experience in senior management roles in large organizations, in both public and private sectors, including Head of Staff of Coca-Cola Israel Group and other lead positions in Coca-Cola and the IBA (Israel Broadcasting Authority). She also served as Head of Foreign Relations and Director of Operations to the IDF attaché at the Israel Embassy in Paris.
Elinor holds a BA (cum laude) in International Relations and Social Sciences from The Hebrew University of Jerusalem and served as an officer in the IDF's prestigious Unit 8200.
Job Titles:
- Founder / CEO of Support2Israel
- Intern
Ezra is an intern at aMoon, where he supports the Growth Investment team's efforts for new and existing investments.
Ezra is the Founder/CEO of Support2Israel, a charity that supplies critical protective and medical equipment to IDF soldiers and frontline Israeli forces, founded in the wake of the October 7th attack.
Ezra is a 2024 Birthright Excel fellow, a highly selective program designed to help foster the next generation of Global Jewish business leaders. Participants join a 10-week summer intensive before joining the global community, receiving lifelong support in both the personal and professional spheres.
Job Titles:
- Advisor
- VP of Investor Relations
Gaby is the VP of Investor Relations at aMoon, responsible for fostering and managing relationships with the Fund's global investor base and overseeing all marketing, communications, and brand strategy.
Gaby's transition into HealthTech was a natural one, fueled by her excitement for the industry's fast pace and rapid innovation. She was drawn to aMoon by her desire to support some of the most promising scientists by bringing their transformative and groundbreaking technologies to market and accelerating cure to benefit people globally.
Gaby brings a wealth of experience to aMoon, including work with philanthropists, entrepreneurs, investors, members of the press, and media consultants. Prior to joining aMoon, she was the Chief Development Officer at Shalva, the Israel Association for the Care and Inclusion of Persons with Disabilities. At Shalva, Gaby played a key role in managing the global network of development offices, creating strategic initiatives to further Shalva's mission and drive change through the influence of a global Advisory Council.
Originally from the UK, Gaby qualified as a Planning and Development Surveyor with a large UK property company and later went on to join Tesco, the UK's largest retailer as a Change Acceleration Consultant where she was responsible for developing and delivering large-scale innovative change projects across the organization.
Gaby has a BSc. Hons in Urban Estate Management and was a member of the Royal Institute of Chartered Surveyors prior to moving to Israel.
Job Titles:
- Associate
- Associate at AMoon Growth
Hagai is an Associate at aMoon Growth, where he draws on his scientific and industry background to source and evaluate late-stage investment opportunities in life science tools and diagnostics.
Before joining aMoon, Hagai built deep expertise across molecular diagnostics, therapeutics, and disease biology. He served as Platform Team Lead at 1E Therapeutics, spearheading the development of oligonucleotide-based therapies. Earlier, at Rosetta Genomics, he contributed to the full lifecycle of cancer diagnostic test development.
Hagai earned his MSc and PhD from the Weizmann Institute of Science, where his research uncovered novel mechanisms in ALS and was published in Molecular Cell. He then joined Massachusetts General Hospital and Harvard Medical School as a staff scientist, leading translational research efforts in neurodegeneration and pain.
Job Titles:
- Advisor
- Certified Public Accountant
- Chief Financial Officer
Irena is the Chief Financial Officer at aMoon, where she is responsible for all of the Fund's financial functions, including reporting, treasury and corporate finance.
Irena brings over 15 years of finance management experience in public companies and business units of global enterprises. She oversees the finance and operations support provided to all functions within the organization, assisting senior management in financial planning and results management, she leads financial and tax due diligence processes, and analyzes portfolio companies financial and business results.
Prior to joining aMoon, Irena was the VP of Finance at Alcobra (NASDAQ: ADHD) a development-stage biotech company, where she led the financial aspects of Alcobra's operations, playing a key role in Public equity offering and Alcobra's merger with Arcturus Therapeutics (NASDAQ: ARCT), a San-Diego based mRNA company.
Prior to joining Alcobra, she was Finance Manager at Omrix Biopharmaceuticals, a Johnson & Johnson company, where she spent seven years in various finance positions.
Irena is passionate about being part of an organization that enables companies to develop technologies which may save lives.
Irena is a Certified Public Accountant and holds a B.A. in Economics and Accounting from the Hebrew University of Jerusalem and an M.B.A. from Tel Aviv University.
Isaac Devash is a Venture Partner at aMoon and was instrumental in establishing aMoon Growth, aMoon Velocity, and the 8400 Health Network.
After completing his four years of service as an officer in the Israel Defense Forces, Isaac proactively pursued the development of a global career. He initially worked in Latin America and then moved on to study at the Wharton Business School at the University of Pennsylvania, gaining his B.A. degree in less than 2.5 years (summa cum laude). Isaac then worked as an international investment banker specializing in mergers and acquisitions at Credit Suisse First Boston- located first in NYC, then moving to London and Tokyo. Following his banking tenure, he gained experience in international private equity and venture capital and also earned an MBA from the Harvard Business School.
Isaac then returned to Israel, where he initially managed the Renaissance Fund and then established the Israel International Funds. Before joining aMoon, Isaac was a Senior Advisor to Permira (a British global PE firm) in its purchase of Netafim (acquired for $850M, sold for $1.9B), and to ex-Permira members who purchased Lumenis (acquired for $512M, sold at $1.2B).
In parallel to his business career, Isaac dedicates a substantial part of his time and energy to public service on a pro-bono basis. He has served as an economic advisor to the Israeli government in numerous capacities and a variety of committees that have structurally reformed the Israeli capital markets. He has passionately spent almost 20 years as the co-founder of Atudot Le'Israel, a national initiative comprising some 25 programs meant to strengthen Israel's public service sector by systematically attracting and nurturing a critical mass of managerial and professional talent. Isaac is also the founding Chairman of both the Wharton and Harvard Business School Clubs of Israel.
Jim Weissman is a life sciences industry veteran, bringing over 30 years of experience in various roles such as business and corporate development, general management, marketing, mergers and acquisitions, and new product planning and development.
Currently, he is the principal of JBW Consulting LLC, specializing in biotech consulting with a focus on business and corporate development, along with serving as an independent board member for Cerberus Therapeutics and Telesis Bio.
Previously, Jim held the positions of EVP, COO and CBO, at Dicerna Pharmaceuticals, where he played a key role in securing significant business development deals with major industry players such as Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche, leading to the company's acquisition by Novo Nordisk in 2021.
Before his tenure at Dicerna, he was the vice president of business development at MannKind Corporation. His earlier experience includes leadership roles in business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, Japan, and various commercial and leadership positions at Pharmacia Biotech across the USA, Sweden, Japan, and the UK.
Jim holds a Bachelor of Science degree from Bates College.
Lloyd B. Minor, MD, is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine.
Under his leadership, Stanford Medicine has pioneered the Precision Health revolution, which emphasizes preventive, personalized health care and leverages advances in biomedicine to treat and cure complex diseases. His book, "Discovering Precision Health," illustrates how Stanford Medicine and other health leaders are revolutionizing biomedicine.
In 2021, Dr. Minor articulated and began realizing a bold vision to transform the future of life sciences at Stanford University and beyond - a multi-decade journey enabled by Precision Health.
Dr. Minor also is a professor of Otolaryngology-Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy. With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders.
In 2012, he was elected to the National Academy of Medicine.
Job Titles:
- Marketing Communications Manager
Moshic Mor is a General Partner at aMoon, where he co-leads Velocity, our early-stage investment fund for highly disruptive healthcare technologies. As a successful entrepreneur, Moshic knows firsthand the challenges entrepreneurs face, and what it takes to build a highly successful company.
Noah Lasson - Chief Compliance Officer
Job Titles:
- Advisor
- Chief Compliance Officer
- CISO
Job Titles:
- Advisor
- Chief Legal Officer
Job Titles:
- Advisor
- Chief of Staff
- Chief People Officer
Job Titles:
- Portfolio Manager
- Portfolio Manager for AMoon Edge
Patrick is a Portfolio Manager for aMoon Edge, where he helps to oversee the fund's public healthcare investments and also leads private therapeutics investments for aMoon Growth. Prior to joining aMoon in August of 2024, Patrick was a Managing Director and Head of Research at Aquilo Capital Management, a biotechnology-dedicated investment fund focused primarily on small- and mid-cap public therapeutics companies, with a lens towards deep fundamental analysis and value-based investment principles. He has always believed strongly in the positive impact that novel drug development can have for society and is honored to contribute to this ecosystem of amazing scientists and entrepreneurs.
Patrick began his career as a bench scientist in drug development, with a spectrum of roles in discovery and early development for novel biologic and small molecule drugs. This experience includes protein engineering and cell line development for monoclonal antibodies at Xoma, target validation and protein biochemistry for kinase inhibitors at Exelixis, and platform development for expression of antibody-drug conjugates and bispecific antibodies at Sutro Biopharma. Since 2018, he has also been the chair of the Business Development and Finance Committee for ISCT, the International Society for Cellular Therapy, leading a team of biopharmaceutical senior executives with initiatives to connect the investment and cell therapy product development communities.
Patrick received his MBA from UC Berkeley's Haas School of Business and his Bachelor of Science degree in Chemical Engineering from UCLA, with a specialization in biomedical applications.
Robert Langer is one of 10 Institute Professors at the Massachusetts Institute of Technology (MIT), the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited over 332,000 times; his h-index of 285 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have been licensed or sublicensed to over 400 companies. He served as Chairman of the FDA's Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 34 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.
Job Titles:
- Advisor
- Partner at AMoon Velocity
Roy is a Partner at aMoon Velocity, where he leads deal teams, manages sourcing, and sits on the boards of IBEX Medical Analytics and Eleos Health. Additionally, he leads StarFinder Lab, our collaboration with Roche Diagnostics.
Job Titles:
- Retired Executive from Bristol Myers Squibb
- Venture Partner
Samuel Moed is a recently retired executive from Bristol Myers Squibb (BMS; NYSE: BMY), a global biopharma company focused on innovative therapeutics. In his most recent capacity as Senior Vice President, Corporate Strategy, Samuel led the strategic direction of the company with close linkage to all of its major businesses, functions, and geographies. Recent focus was on the $90 billion acquisition and integration of Celgene by BMS. Previously, Samuel oversaw strategy for BMS's Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare.
Job Titles:
- HR Generalist, Executive Assistant & Office Manager
Job Titles:
- Principal
- Principal at AMoon Growth
Tamir is a Principal at aMoon Growth, focusing on investments in late-stage HealthTech companies. In this capacity, he identifies and analyzes opportunities at the intersection of health and technology, working closely with management teams to contribute to their value creation journey.
Having been an integral part of aMoon since its inception, Tamir has played a meaningful role in the firm's growth. His analytical mindset and critical thinking have helped solidify a culture of debriefing, continuous learning, and lessons implementation within the fund, bringing a differentiated perspective to the team.
Before transitioning to the venture capital arena, Tamir spent six years as an officer with the Israeli Navy SEALs unit, Shayetet 13. Throughout this period, he demonstrated leadership skills while leading diverse and highly specialized teams, and he remains committed to bringing this collaborative culture to the fund. Beyond his military service, Tamir assumed leadership roles in several non-profit initiatives, where he continues to serve as a mentor and advisor.
With his family's background deeply rooted in healthcare, Tamir's personal connection to aMoon's mission is evident. He is dedicated to leveraging technology to enhance both quality and access to care, ultimately accelerating cure.
Tamir holds an MBA from Stanford Graduate School of Business, where he spent much of his time deepening his expertise in solutions for the aging population. Additionally, he earned an MA in Finance and LLB in Law (Cum Laude) from Reichman University in Israel.
Todd Sone is a General Partner at aMoon, where he brings over 20 years of healthcare investment experience as a sell side analyst, LP, and buy side investor to co-lead our Growth team. As a student, Todd worked part-time in his father's pharmaceutical warehouse, which inspired him to pursue a career in the healthcare industry. His greatest passion is working with entrepreneurs to bring transformative products to market.
Todd sits on the boards of Biolojic Design, MOBILion, Scipher Medicine, Theranica, and Ultima Genomics. Before joining aMoon, Todd was a Managing Director at Signet Healthcare Partners, an investment fund that provides growth capital to commercial-stage life-science companies. He co-led the investment in Claris Lifesciences (sold to Baxter), and served on the boards of Arbor Pharmaceuticals (sold to KKR), Apicore (sold to Medicure), and Smart Medical Systems.
Prior to Signet, Todd served as an Investment Director at Joddes, a family office with interests in numerous lifescience companies, including Pharmascience, Medicom and Paladin Labs. Earlier in his career, Todd was an equity analyst at Morgan Stanley and Goldman Sachs in New York, covering the US pharmaceutical sector. He started his career as a strategy consultant with Mercer Management Consulting.
Todd received a Bachelor of Commerce with High Distinction from the University of Toronto, and an MBA from The Wharton School at the University of Pennsylvania with concentrations in healthcare management and finance.
Job Titles:
- Head of Novo Nordisk 's Bio Innovation Hub
Uli Stilz is Head of Novo Nordisk's Bio Innovation Hub in Boston. In this role, he leads a cross functional R&D team developing innovative partnership models with biotech, venture capital, and academia to co-create novel therapies and technologies to provide life changing treatments for people living with cardiometabolic and rare diseases. Uli graduated with a Master degree in Organic Chemistry from ETH Zürich. He then moved to the Max-Planck-Institute of Biochemistry in Martinsried, where he received his Ph.D. in 1990. After postdoctoral studies at the California Institute of Technology, he joined Hoechst AG where he held various positions before he was appointed Associate Vice President of the newly established Innovation unit within the Diabetes Division at Sanofi in 2010. Over a period of 20 years, he contributed to more than 60 preclinical and clinical drug candidates across cardiometabolic, immunology, and oncology therapy areas. Between 2012 and 2014 he was President of the European Federation for Medicinal Chemistry. In 2014, Uli joined Novo Nordisk A/S in Copenhagen and in 2019 relocated to Boston to create and lead the Novo Nordisk Bio Innovation Hub.
Job Titles:
- Partner
- Partner at AMoon Velocity
Yael is a Partner at aMoon Velocity & Head of aMoon Alpha, an internal value creation unit charged with translating aMoon's unique scale, talent, and global network into concrete competitive advantages and growth opportunities for our portfolio companies. At Velocity, Yael manages sourcing, evaluation, and strategic collaborations, as well as providing support to aMoon in a cross-functional manner to strengthen pharma partnerships and collaborations.
With 15 years of experience in the Healthcare space, Yael's professional journey as a HealthTech investor is underlined by a patient-centric drive for success. Committed to advancing Israel's HealthTech growth engine, she believes that through strategic investments we are able to transform and improve the lives of patients.
As General Manager of Medison Ventures, she has led multiple licensing deals, scouting initiatives for over 15 pharmaceutical companies and has been collaborating with academia and the biotech industry - and led series A investments (and onwards) focused primarily on orphan drugs and genetic diseases.
Previously, Yael led Medical Affairs for the Rare Disease Division of Medison Pharma launching over 10 products. Yael advised to multiple platform companies on platform to product strategy and early partnership deal structures.
With her managerial experience, Yael has led collaborations and effective teamwork across functions and companies. Yael co-founded Andlit Therapeutics and WE@HealthTech - a collaboration with 8400 to build-up female leadership talent in HealthTech.
Yael holds academic degrees in molecular genetics (PhD, Post doc) and a DMD from the Hebrew University of Jerusalem and the Weizmann Institute of Sciences. She is a co-author of multiple scientific publications and is highly involved in pro-bono medical-scientific support of the rare disease community.
Job Titles:
- Advisor
- General Partner
- General Partner & Head of AMoon Alpha
Yaron Daniely is a General Partner, where he co-leads Velocity, an early-stage investment fund pursuing disruptive, cutting-edge technologies with the potential to accelerate cure.
Born in Israel and raised in Florida, Yaron was fascinated by science, medicine, and technology from a young age. Driven by a passion for discovering and creating novel solutions, and a persistent quest for challenging the status quo wherever he went, Yaron spent much of his career leading innovative HealthTech companies. He brings to aMoon a wealth of hands-on experience as a business leader in both the private and public sectors. In return, aMoon fulfills his craving for cutting-edge science and strategic thinking, applied to the creation and mentorship of young companies focused on impacting people's health.
Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University's acclaimed Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network (ITTN), where he converted academic research into practical projects and technologies. Before leading Yissum, he spent 14 years as a senior executive - and 10 years as CEO - of private and NASDAQ-traded Biopharma and Biotech companies. He also co-founded and served as the director of Israel's first and leading MBA program for professionals in the local Biomedical industry at the College of Management Academic Studies for 10 years.
Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, he served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion - Israel Institute of Technology.